All In Biotech

Drug Trial Radar · NCT05155254

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)

Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

407

Actual

Start

May 17, 2022

Primary completion

May 30, 2025

Study completion Sep 2027

Sponsor

Lead sponsor
IO BiotechIndustry
Sponsor type
Industry
Collaborators
Syneos Health; Merck Sharp & Dohme LLC
First posted
Dec 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma. Patients will be stratified on the basis of the following factors; Disease stage: Stage III (unresectable) and IV M1a-b versus stage IV M1c-d and BRAFV600 mutation status: mutated vs wild type. All patients will receive pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment). Patients randomized to IO102-IO103 dual-antigen, immunotherapeutic arm will also be given IO102-IO103 Q3W with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102 IO103 will thereafter be administered subcutaneous every 3 weeks during the maintenance period. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years of treatment). The primary objective is to investigate the efficacy of IO102-IO103 in combination with pembrolizumab (compared with pembrolizumab alone) in terms of progression free survival.

Conditions

  • Metastatic Melanoma
  • Unresectable Melanoma

Interventions

  • IO102-IO103Drug

    IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously

  • PembrolizumabDrug

    Pembrolizumab administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Approximately 3.5 years

Locations

112 sites in 16 countries. Site status is shown where the registry gives one.

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Roswell Park Cancer Institute

    Buffalo, New York

  • VCU Massey Cancer Center

    Richmond, Virginia

  • Sunshine Coast University Hospital

    Birtinya, Australia

  • Peter MacCallum Cancer Centre PMCC - East Melbourne

    Melbourne, Australia

  • Border Medical Oncology Research Unit

    Albury, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Southern Medical Day Care Centre

    Wollongong, New South Wales, Australia

  • Cairns Hospital

    Cairns, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • AZ Nikolaas

    Sint-Niklaas, Belgium

  • Universitair Ziekenhuis Gent UZ Gent

    Ghent, Oost-Vlaanderen, Belgium

  • FNHK Klinika onkologie a radioterapie

    Hradec Králové, Czechia

  • Fakultni Nemocnice Olomouc

    Olomouc, Czechia

  • FN Ostrava

    Ostrava, Czechia

  • FNKV Department of Dermatology

    Prague, Czechia

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Herlev og Gentofte Hospital

    Herlev, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Centre Hospitalier Universitaire de Besançon Jean Minjoz

    Besançon, France

  • Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre

    Bordeaux, France

  • Hopital Ambroise

    Boulogne-Billancourt, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Chu Grenoble - Hopital Albert Michallon

    La Tronche, France

  • Centre Hospitalier Universitaire de Lille

    Lille, France

  • Hôpital de La Timone

    Marseille, France

  • CHU de Nice Hpital de lArchet 2

    Nice, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Eugene Marquis

    Rennes, France

  • Institut de Cancérologie de L'Ouest

    Saint-Herblain, France

  • Centre Hospitalier de Valence (CHV)

    Valence, France

  • Gustave Roussy

    Villejuif, France

  • Universitatsklinikum Augsburg Medizincampus Sued

    Augsburg, Germany

  • Charite Universitaetsmedizin Berlin

    Berlin, Germany

  • St. Josef Hospital - Ruhr-Universitt Bochum

    Bochum, Germany

  • University Hospital Erlangen

    Erlangen, Germany

  • Universitaetsklinikum Essen

    Essen, Germany

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.